{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Disease+to+Soft+Tissue&page=2", "query": { "condition": "Metastatic Disease to Soft Tissue", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Disease+to+Soft+Tissue&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-26T18:48:28.162Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00134030", "title": "Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Localized Osteosarcoma", "Metastatic Osteosarcoma" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Peginterferon Alfa-2b", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER", "PROCEDURE" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "5 Years to 40 Years" }, "enrollment_count": 1334, "start_date": "2005-11-14", "completion_date": "2022-09-30", "has_results": true, "last_update_posted_date": "2023-06-07", "last_synced_at": "2026-06-26T18:48:28.162Z", "location_count": 186, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 132 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00134030" }, { "nct_id": "NCT06760819", "title": "A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "HER2 Mutation" ], "interventions": [ { "name": "BAY2927088", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 111, "start_date": "2025-02-13", "completion_date": "2027-10-25", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-06-26T18:48:28.162Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Duarte, California • Fort Myers, Florida + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06760819" }, { "nct_id": "NCT05135975", "title": "A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroblastoma", "Sarcoma" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nationwide Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Months", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Months to 40 Years" }, "enrollment_count": 86, "start_date": "2022-07-20", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2025-08-12", "last_synced_at": "2026-06-26T18:48:28.162Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Aurora, Colorado • Washington D.C., District of Columbia + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "The Bronx", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05135975" }, { "nct_id": "NCT03454451", "title": "CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer", "Renal Cell Cancer", "Colorectal Cancer", "Triple Negative Breast Cancer", "Cervical Cancer", "Ovarian Cancer", "Pancreatic Cancer", "Endometrial Cancer", "Sarcoma", "Squamous Cell Carcinoma of the Head and Neck", "Bladder Cancer", "Metastatic Castration Resistant Prostate Cancer", "Non-hodgkin Lymphoma" ], "interventions": [ { "name": "CPI-006", "type": "DRUG" }, { "name": "CPI-006 + ciforadenant", "type": "DRUG" }, { "name": "CPI-006 + pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corvus Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 117, "start_date": "2018-04-25", "completion_date": "2023-02-19", "has_results": false, "last_update_posted_date": "2023-12-21", "last_synced_at": "2026-06-26T18:48:28.162Z", "location_count": 22, "location_summary": "Tucson, Arizona • Duarte, California • San Francisco, California + 18 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03454451" }, { "nct_id": "NCT00623077", "title": "MT2004-30: Tomotherapy for Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Kidney Cancer", "Liver Cancer", "Retinoblastoma", "Sarcoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "thiotepa", "type": "DRUG" }, { "name": "stem cell transplantation", "type": "PROCEDURE" }, { "name": "tomotherapy", "type": "RADIATION" }, { "name": "total marrow irradiation", "type": "RADIATION" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Whole lung radiation", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "70 Years", "sex": "ALL", "summary": "Up to 70 Years" }, "enrollment_count": 23, "start_date": "2005-08", "completion_date": "2016-10", "has_results": false, "last_update_posted_date": "2017-12-05", "last_synced_at": "2026-06-26T18:48:28.162Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00623077" }, { "nct_id": "NCT01374672", "title": "Biomarkers in Predicting Response to Chemotherapy in Samples From Young Patients With Osteosarcoma", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Localized Osteosarcoma", "Metastatic Osteosarcoma", "Osteoblastic Osteosarcoma", "Recurrent Osteosarcoma" ], "interventions": [ { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "20 Years", "sex": "ALL", "summary": "10 Years to 20 Years" }, "enrollment_count": 20, "start_date": "2011-07", "completion_date": "2011-09", "has_results": false, "last_update_posted_date": "2015-05-12", "last_synced_at": "2026-06-26T18:48:28.162Z", "location_count": 1, "location_summary": "Monrovia, California", "locations": [ { "city": "Monrovia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01374672" }, { "nct_id": "NCT01694277", "title": "Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastrointestinal Stromal Tumors" ], "interventions": [ { "name": "Masitinib", "type": "DRUG" }, { "name": "Sunitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AB Science", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 258, "start_date": "2012-04", "completion_date": "2020-12", "has_results": false, "last_update_posted_date": "2020-12-08", "last_synced_at": "2026-06-26T18:48:28.162Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01694277" }, { "nct_id": "NCT00036712", "title": "Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Kidney Cancer", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Neuroblastoma", "Oral Complications", "Ovarian Cancer", "Pain", "Sarcoma" ], "interventions": [ { "name": "management of therapy complications", "type": "PROCEDURE" }, { "name": "pain therapy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "2 Years to 18 Years" }, "enrollment_count": 80, "start_date": "2002-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-20", "last_synced_at": "2026-06-26T18:48:28.162Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00036712" }, { "nct_id": "NCT05824975", "title": "A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Metastatic Solid Tumor", "Soft Tissue Sarcoma (STS)", "Platinum-resistant Ovarian Cancer (PROC)", "Hepatocellular Carcinoma (HCC)", "Colorectal Cancer (CRC)", "HER2 Negative Breast Cancer", "Cutaneous Melanoma", "Renal Cell Carcinoma (RCC)" ], "interventions": [ { "name": "GI-102 subcutaneous (SC)", "type": "DRUG" }, { "name": "GI-102", "type": "DRUG" }, { "name": "doxorubicin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "bevacizumab", "type": "DRUG" }, { "name": "eribulin", "type": "DRUG" }, { "name": "trastuzumab deruxtecan (T-DXd)", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GI Innovation, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 358, "start_date": "2023-05-30", "completion_date": "2027-04-24", "has_results": false, "last_update_posted_date": "2024-11-25", "last_synced_at": "2026-06-26T18:48:28.162Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05824975" }, { "nct_id": "NCT06440005", "title": "A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer", "Advanced Cancer", "Locally Advanced Carcinoma", "Metastatic Solid Tumor", "Breast Cancer", "Prostate Cancer", "Colorectal Cancer", "Pancreatic Cancer", "Liver Cancer", "Angiosarcoma", "Solid Tumor" ], "interventions": [ { "name": "AGX101", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Angiex, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2024-07-22", "completion_date": "2027-09-06", "has_results": false, "last_update_posted_date": "2026-02-11", "last_synced_at": "2026-06-26T18:48:28.162Z", "location_count": 6, "location_summary": "Los Angeles, California • Sarasota, Florida • St Louis, Missouri + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06440005" } ] }